Designing robust clinical trials to evaluate antioxidant therapies in HTN and DM requires addressing unique challenges, including patient heterogeneity, biomarker variability, and the dual role of OS as both cause and consequence of disease progression
doi: 10.3389/fncel.2024.1365448 Received 04 January 2024 Accepted 19 June 2024 Published 03 July 2024 Volume 18 - 2024 Edited by Pei Shang, Mayo Clinic, United States Reviewed by Akira Monji, Saga University, Japan Jie Xiao, Shanghai Jiao Tong University, China Updates Copyright 2024 Li, Li, Fang, Chen, Yu and Zhu
HCG [ 11,000 IU VIAL ] Tear out the inner seal from the hCG vial and wipe the top with alcohol swab Remove cap from the provided water ( Bacteriostatic Sodium Chloride 0.9% Only ) and wipe the top with alcohol swab Using a Mixing syringe with needle, turn the bottle of water upside down and insert needle
| 04.29.26 | 8 min read
Lessen emotional eating by enhancing mood and energy stability